Tyr172

Site Information
tRILSIMyyAREPGK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3672568

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 )
Disease tissue studied:	cervical cancer ( 1 ) , cervical adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	HeLa S3 (cervical) ( 1 )

Upstream Regulation
Treatments:	nocodazole ( 1 )

References
1	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
2	Yu J (2006) CST Curation Set: 2143; Year: 2006; Biosample/Treatment: tissue, larynx/-; Disease: laryngeal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info

References

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231 Curated Info

Yu J (2006) CST Curation Set: 2143; Year: 2006; Biosample/Treatment: tissue, larynx/-; Disease: laryngeal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info